Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05527184 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
A Phase 1 study of Endometrial Cancer and Cervical Cancer, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 256
- Enrollment target
- 20
- Study locations
NCT05527184: Active Phase 1 study of Endometrial Cancer and Cervical Cancer, sponsored by AbbVie.
NCT05527184 is a Phase 1 study of Endometrial Cancer and Cervical Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 256 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05527184, a Phase 1 study of Endometrial Cancer and Cervical Cancer, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 256 participants
- Enrollment target
- 20
- Study locations
Study Summary
IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.
Conditions Studied
Interventions
- DRUG IMGN151
Study Locations (20)
California
- City of Hope National Medical Center /ID# 269036 - Duarte
- Moores Cancer Center /ID# 269040 - La Jolla
- University of California Los Angeles Medical Center /ID# 269037 - Los Angeles
- Hoag Memorial Hospital Presbyterian /ID# 269047 - Newport Beach
Florida
- AdventHealth Celebration /ID# 269030 - Kissimmee
- Mount Sinai Medical Center /ID# 269050 - Miami
- Miami Cancer Institute at Baptist Health /ID# 269041 - Miami
- Florida Cancer Specialists- Sarasota Cattlemen /ID# 269055 - Sarasota
New York
- Roswell Park Cancer Institute /ID# 269043 - Buffalo
- Long Island Jewish Medical Center /ID# 269035 - New Hyde Park
- Columbia University Irving Medical Center /ID# 269033 - New York
Massachusetts
- Massachusetts General Hospital /ID# 278119 - Boston
- Dana-Farber Cancer Institute /ID# 269039 - Boston
Alabama
- University of Alabama at Birmingham /ID# 269045 - Birmingham
Colorado
- UCHSC Anschultz Cancer Pavilion /ID# 269056 - Aurora
Illinois
- University of Chicago Medical Center /ID# 269028 - Chicago
Michigan
- Karmanos Cancer Institute - Detroit /ID# 269052 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What the registry record for NCT05527184 still lists
NCT05527184 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (51% lower).
The record links to 5 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which IMGN151 is the first listed.
NCT05527184 names 20 study sites across 11 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05527184 about?
NCT05527184 is a clinical study titled "First in Human Study of IMGN151 in Recurrent Gynaecological Cancers". IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; r...
What is the current status of trial NCT05527184?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 256 participants. The study started on 2023-01-11. Estimated completion is 2027-02.
What conditions does trial NCT05527184 study?
This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma of Ovary.
What interventions are being tested in trial NCT05527184?
The interventions under investigation include: IMGN151 (DRUG).
Who is sponsoring clinical trial NCT05527184?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05527184 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05527184's enrollment target sits among peer trials
256 58th of 181 higher than 124 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI